Gallardo Avilés R GAF. Uso de la vía subcutánea en cuidados paliativos. Monografías SECPAL
2013; 4: 1–48.
Kinnunen, HM, Mrsny, RJ. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Controlled Release
2014; 182: 22–32.
Dychter, SS, Gold, DA, Haller, MF. Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infusion Nursing
2012; 35: 154–60.
Uitto, J, Olsen, DR, Fazio, MJ. Extracellular matrix of the skin: 50 years of progress. J Investigative Dermatology
Supersaxo, A, Hein, WR, Steffen, H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharmaceutical Res
1990; 7: 167–69.
Richter, WF, Bhansali, SG, Morris, ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J
2012; 14: 559–70.
Schoenbeck, SL, McBride, K. Hypodermoclysis: easy, safe, cost-effective. J Practical Nursing
2010; 60: 7–8.
Justad, M. Continuous subcutaneous infusion: an efficacious, cost-effective analgesia alternative at the end of life. Home Healthcare Nurse
2009; 27: 140–47; quiz 8–9.
[Practical advice. Subcutaneous drug administration. An alternative used in palliative care]. Canadian Family Physician
2001; 47: 266–67.
Barua, P, Bhowmick, BK. Hypodermoclysis – a victim of historical prejudice. Age Ageing
2005; 34: 215–17.
O’Keeffe, S, Geoghegan, M. Subcutaneous hydration in the elderly. Irish Medical J
2000; 93: 197–98.
Hussain, NA, Warshaw, G. Utility of clysis for hydration in nursing home residents. J Am Geriatrics Soc
1996; 44: 969–73.
Brown, MK, Worobec, F. Hypodermoclysis. Another way to replace fluids. Nursing
2000; 30: 58–59.
Slesak, G, Schnurle, JW, Kinzel, E, Jakob, J, Dietz, PK. Comparison of subcutaneous and intravenous rehydration in geriatric patients: a randomized trial. J Am Geriatrics Soc
2003; 51: 155–60.
Duems Noriega, O, Arino Blasco, S. [Efficacy of the subcutaneous route compared to intravenous hydration in the elderly hospitalised patient: a randomised controlled study]. Revista espanola de geriatria y gerontologia
2014; 49: 103–7.
Dasgupta, M, Binns, MA, Rochon, PA. Subcutaneous fluid infusion in a long-term care setting. J Am Geriatrics Soc
2000; 48: 795–99.
Challiner, YC, Jarrett, D, Hayward, MJ, al-Jubouri, MA, Julious, SA. A comparison of intravenous and subcutaneous hydration in elderly acute stroke patients. Postgraduate Medical J
1994; 70: 195–97.
Arinzon, Z, Feldman, J, Fidelman, Z, Gepstein, R, Berner, YN. Hypodermoclysis (subcutaneous infusion) effective mode of treatment of dehydration in long-term care patients. Archives Gerontology Geriatrics
2004; 38: 167–73.
Lanuke, K, Fainsinger, RL, DeMoissac, D. Hydration management at the end of life. J Palliative Medicine
2004; 7: 257–63.
20.Frisoli Junior, A, de Paula, AP, Feldman, D, Nasri, F. Subcutaneous hydration by hypodermoclysis. A practical and low cost treatment for elderly patients. Drugs Aging
2000; 16: 313–9.
Luk, J CF, Chu, L. Is hypodermoclysis suitahie for frail Chinese elderly? Asian J Gerontology Geriatrics
2008; 3: 49–50.
Lybarger, EH. Hypodermoclysis in the home and long-term care settings. J Infusion Nursing
2009; 32: 40–44.
Turner, T, Cassano, AM. Subcutaneous dextrose for rehydration of elderly patients – an evidence-based review. BMC Geriatrics
2004; 4: 2.
Dychter, SS, Ebel, D, Mead, TR, Yocum, RC. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated Ringer solution administered subcutaneously: a phase IV, double-blind, randomized pilot study in healthy volunteers. Current Therapeutic Res
2009; 70: 421–38.
Mace, SE, Harb, G, Friend, K, Turpin, R, Armstrong, EP, Lebel, F. Cost-effectiveness of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in children with mild to moderate dehydration. Am J Emergency Med
2013; 31: 928–34.
Spandorfer, PR, Mace, SE, Okada, PJ, Simon, HK, Allen, CH, Spiro, DM
A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department. Clinical Therapeutics
2012; 34: 2232–45.
Cockshott, WP, Thompson, GT, Howlett, LJ, Seeley, ET. Intramuscular or intralipomatous injections?
New England J Med
1982; 307: 356–58.
Pramanick, S, Singodia, D, Chandel, V. Excipient selection in parenteral formulation development. Pharma Times
2013; 45: 65–77.
Carpenter, CP, Shaffer, CB. A study of the polyethylene glycols as vehicles for intramuscular and subcutaneous injection. J Pharm Sci
2006; 41: 27–29.
Soler Mieras, A, Santaeugenia Gonzalez, S, Montane Esteva, E. [Administration of subcutaneous antibiotics in patients on palliative care]. Medicina clinica
2007; 129: 236–37.
Robelet, A, Caruba, T, Corvol, A, Begue, D, Gisselbrecht, M, Saint-Jean, O
[Antibiotics given subcutaneously to elderly]. Presse medicale (Paris, France: 1983). 2009; 38: 366–76.
Farias Azevedo, E, De Bortoli, S. Administration of antibiotics subcutaneously: an integrative literature review. Acta Paul Enferm
2012; 25: 6.
Harb, G, Lebel, F, Battikha, J, Thackara, JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Current Medical Res Opinion
2010; 26: 279–88.
Walker, P, Neuhauser, MN, Tam, VH, Willey, JS, Palmer, JL, Bruera, E
Subcutaneous administration of cefepime. J Pain Symptom Management
2005; 30: 170–74.
Champoux, N, Du Souich, P, Ravaoarinoro, M, Phaneuf, D, Latour, J, Cusson, JR. Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. Br J Clin Pharmacol
1996; 42: 325–31.
Barbot, A, Venisse, N, Rayeh, F, Bouquet, S, Debaene, B, Mimoz, O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med
2003; 29: 1528–34.
Frasca, D, Marchand, S, Petitpas, F, Dahyot-Fizelier, C, Couet, W, Mimoz, O. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrobial Agents Chemotherapy
2010; 54: 924–26.
Forestier, E, Gros, S, Peynaud, D, Levast, M, Boisseau, D, Ferry-Blanco, C
[Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea]. Medecine et maladies infectieuses
2012; 42: 440–43.
Plantin, P, Mahe, M, Le Noac’h, E, Le Roy, JP. [Cutaneous necroses after subcutaneous injections of amikacin]. Presse medicale (Paris, France: 1983). 1993; 22: 1366.
Leng, B, Saux, MC, Latrille, J. [Comparative pharmacokinetics of amikacin after intravenous, intramuscular and subcutaneous administration]. La Nouvelle presse medicale
1979; 8: 3421–25.
Duterque, M, Hubert-Asso, AM, Corrard, A. [Necrotic lesions caused by subcutaneous injections of gentamycin and sisomicin]. Annales de dermatologie et de venereologie
1985; 112: 707–8.
Penso, D, Delfraissy, JF, Pham Van, T, Dormont, J. [Skin necrosis following administration of subcutaneous gentamicin]. Presse medicale (Paris, France: 1983). 1984; 13: 1575–76.
Doutre, MS, Beylot, C, Vendeaud-Busquet, M, Bioulac-Sage, P. [Cutaneous necrosis after subcutaneous administration of gentamycin]. Therapie
1985; 40: 266–67.
Courcol, RJ, Pol, A, Dufay, C, Lafitte, C, Martin, GR. Pharmacokinetics of netilmicin administered once or twice-daily by subcutaneous injection. J Antimicrobial Chemotherapy
1986; 18: 646–47.
Cree, M, Stacey, S, Graham, N, Wainwright, C. Fosfomycin – investigation of a possible new route of administration of an old drug. A case study. J Cystic Fibrosis
2007; 6: 244–46.
Verma, AK, da Silva, JH, Kuhl, DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Annals Pharmacotherapy
2004; 38: 544–49.
Goenaga, MA, Millet, M, Sanchez, E, Garde, C, Carrera, JA, Arzellus, E. Subcutaneous furosemide. Annals Pharmacotherapy
2004; 38: 1751.
Tarabini-Castellani, C. Uso subcutáneo de furosemida en insuficiencia cardíaca terminal. Med Pal
2006; 13: 2.
Schein, RJ, Arieli, S. Administration of potassium by subcutaneous infusion in elderly patients. Br Med J
1982; 285: 1167–68.
Aries, PM, Schubert, M, Muller-Wieland, D, Krone, W. [Subcutaneous magnesium pump in a patient with combined magnesium transport defect]. Deutsche medizinische Wochenschrift
2000; 125: 970–72.
Walker, J, Lane, P, McKenzie, C. Evidence-based practice guidelines: a survey of subcutaneous dexamethasone administration. Int J Palliative Nursing
2010; 16: 494–98.
Russell, GM, Durant, C, Ataya, A, Papastathi, C, Bhake, R, Woltersdorf, W
Subcutaneous pulsatile glucocorticoid replacement therapy. Clinical Endocrinology
2014; 81: 289–93.
Oksnes, M, Bjornsdottir, S, Isaksson, M, Methlie, P, Carlsen, S, Nilsen, RM
Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clinical Endocrinol Metabolism
2014; 99: 1665–74.
Gagliardi, L, Nenke, MA, Thynne, TR, von der Borch, J, Rankin, WA, Henley, DE
Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial. J Clinical Endocrinol Metabolism
2014; 99: 4149–57.
Lovas, K, Husebye, ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European J Endocrinol
2007; 157: 109–12.
Hahner, S, Burger-Stritt, S, Allolio, B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. European J Endocrinol
2013; 169: 147–54.
Pecking, M, Montestruc, F, Marquet, P, Wodey, E, Homery, MC, Dostert, P. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. Br J Clinical Pharmacol
2002; 54: 357–62.
Gremaud, G, Zulian, GB. Indications and limitations of intravenous and subcutaneous midazolam in a palliative care center. J Pain Symptom Management
1998; 15: 331–33.
Greenblatt, DJ, Blaskovich, PD, Nuwayser, ES, Harmatz, JS, Chen, G, Zinny, MA. Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. J Clinical Pharmacol
2005; 45: 1288–93.
Smales, OR, Smales, EA, Sanders, HG. Flunitrazepam in terminal care. J Paediatrics Child Health
1993; 29: 68–69.
Tanguy-Goarin, C, Cogulet, V. Drugs administration by subcutaneous injection within palliative care. Therapie
2010; 65: 525–31.
Kennett, A, Hardy, J, Shah, S, A’Hern, R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Supportive Care in Cancer
2005; 13: 715–21.
Eisenchlas, JH, Garrigue, N, Junin, M, De Simone, GG. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliative Medicine
2005; 19: 71–75.
McCabe, HL, Maraveyas, A. Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE). Anticancer Res
2003; 23: 5209–12.
O’Neill, J, Fountain, A. Levomepromazine (methotrimeprazine) and the last 48 hours. Hospital Medicine
1999; 60: 564–67.
Elsayem, A, Bush, SH, Munsell, MF, Curry, E 3rd, Calderon, BB, Paraskevopoulos, T
Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Management
2010; 40: 774–82.
Lopez-Saca, JM, Vaquero, J, Larumbe, A, Urdiroz, J, Centeno, C. Repeated use of subcutaneous levetiracetam in a palliative care patient. J Pain Symptom Management
2013; 45: e7–8.
Remi, C, Lorenzl, S, Vyhnalek, B, Rastorfer, K, Feddersen, B. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects. J Pain Palliative Care Pharmacotherapy
2014; 28: 371–77.
Dosda, R, Marti-Bonmati, L, Ronchera-Oms, CL, Molla, E, Arana, E. Effect of subcutaneous butylscopolamine administration in the reduction of peristaltic artifacts in 1.5-T MR fast abdominal examinations. European Radiology
2003; 13: 294–98.
70De Conno, F, Caraceni, A, Zecca, E, Spoldi, E, Ventafridda, V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Management
1991; 6: 484–86.
Kintzel, PE, Chase, SL, Thomas, W, Vancamp, DM, Clements, EA. Anticholinergic medications for managing noisy respirations in adult hospice patients. Am J Health-system Pharmacy
2009; 66: 458–64.
Reichmann, JP, Kirkbride, MS. Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy. Managed Care
2012; 21: 44–47.
Klauser, CK, Fox, NS, Istwan, N, Rhea, D, Rebarber, A, Desch, C
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. Am J Perinatology
2011; 28: 715–21.
Sadaba, B, del Barrio, A, Campanero, MA, Azanza, JR, Gomez-Guiu, A, Lopez-Picazo, JM
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. PloS One
2014; 9: e89747.
Gurpide, A, Sadaba, B, Martin-Algarra, S, Azanza, JR, Lopez-Picazo, JM, Campanero, MA
Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy. The Oncologist
2007; 12: 1151–55.
Varma, S, Deakin, J, Claydon, PJ. Subcutaneous cyclizine. Anaesthesia
2001; 56: 919–20.
Vella-Brincat, JW, Begg, EJ, Jensen, BP, Chin, PK, Roberts, RL, Fairhall, M
The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. J Pain Symptom Management
2012; 43: 540–48.
Desmidt, T, Constans, T. Subcutaneous infusion of esomeprazole in elderly patients in palliative care: a report of two cases. J Am Geriatrics Soc
2009; 57: 1724–25.
Agar, M, Webster, R, Lacey, J, Donovan, B, Walker, A. The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients. J Pain Symptom Management
2004; 28: 529–31.
Duncan, AR, Hardy, JR, Davis, CL. Subcutaneous ketorolac. Palliative Medicine
1995; 9: 77–78.
Menegaldo, L. [The subcutaneous administration of a NSAID in palliative care]. La Clinica terapeutica
1992; 141: 273–78.
Zeitlinger, M, Rusca, A, Oraha, AZ, Gugliotta, B, Muller, M, Ducharme, MP. Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. Int J Clin Pharmacol Therapeutics
2012; 50: 383–90.
Chiarello, E, Bernasconi, S, Gugliotta, B, Giannini, S. Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (DIRECT study): a randomized trial. Pain Practice: the official journal of World Institute of Pain. 2013.
Derry, CJ, Derry, S, Moore, RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Systematic Reviews
2012; 2: Cd009665.
Moore, JC, Miner, JR. Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache. Patient Preference and Adherence
2012; 6: 27–37.
Nelson, KA, Glare, PA, Walsh, D, Groh, ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Management
1997; 13: 262–67.
Elsner, F, Radbruch, L, Loick, G, Gaertner, J, Sabatowski, R. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliative Medicine
2005; 8: 743–50.
Anderson, SL, Shreve, ST. Continuous subcutaneous infusion of opiates at end-of-life. Annals Pharmacotherapy
2004; 38: 1015–23.
Hunt, R, Fazekas, B, Thorne, D, Brooksbank, M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Management
1999; 18: 111–19.
Thomas, JR, Wallace, MS, Yocum, RC, Vaughn, DE, Haller, MF, Flament, J. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Management
2009; 38: 663–72.
Walsh, D, Perin, ML, McIver, B. Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hospice Palliative Care
2006; 23: 353–59.
Stuart-Harris, R, Joel, SP, McDonald, P, Currow, D, Slevin, ML. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol
2000; 49: 207–14.
Kestenbaum, MG, Vilches, AO, Messersmith, S, Connor, SR, Fine, PG, Murphy, B
Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Medicine
2014; 15: 1129–53.
Watanabe, S, Pereira, J, Hanson, J, Bruera, E. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Management
1998; 16: 323–26.
Miller, RS, Peterson, GM, Abbott, F, Maddocks, I, Parker, D, McLean, S. Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. Br J Clin Pharmacol
1995; 40: 553–56.
Paix, A, Coleman, A, Lees, J, Grigson, J, Brooksbank, M, Thorne, D
Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain
1995; 63: 263–69.
Watanabe, S, Pereira, J, Tarumi, Y, Hanson, J, Bruera, E. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. J Palliative Med
2008; 11: 570–74.
Vadivelu, N, Hines, RL. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Management
2007; 3: 49–58.
Khajavi, MR, Aghili, SB, Moharari, RS, Najafi, A, Mohtaram, R, Khashayar, P
Subcutaneous tramadol infiltration at the wound site versus intravenous administration after pyelolithotomy. Annals Pharmacotherapy
2009; 43: 430–35.
Rotshteyn, Y, Boyd, TA, Yuan, CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol
2011; 7: 227–35.
Ladanyi, A, Temkin, SM, Moss, J. Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user. Int J Gynecol Cancer
2010; 20: 308–10.
Candy, B, Jones, L, Goodman, ML, Drake, R, Tookman, A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Systematic Reviews
2011; (1): Cd003448.
Raj, G, Kumar, R, McKinney, WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Archives Internal Med
1999; 159: 2721–24.
Mottice, BL, Soric, MM, Legros, E. Effect of intravenous versus subcutaneous phytonadione on length of stay for patients in need of urgent warfarin reversal. Am J Therapeutics
2014; published ahead of print.
Guerci, B, Sauvanet, JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metabolism
2005; 31: 4s7–4s24.
Gutniak, MK, Linde, B, Holst, JJ, Efendic, S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care
1994; 17: 1039–44.
Young, MA, Wald, JA, Matthews, JE, Scott, R, Hodge, RJ, Zhi, H
Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgraduate Med
2014; 126: 84–97.
Scott, LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs
2014; 74: 2161–74.
Sanford, M. Dulaglutide: first global approval. Drugs
2014; 74: 2097–103.
[Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy]. Medicina clinica
(suppl 2): 12–7.
Gerich, J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J General Med
2013; 6: 877–95.
Clarke, BL, Kay Berg, J, Fox, J, Cyran, JA, Lagast, H. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1–84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clinical Therapeutics
2014; 36: 722–36.
Mystakidou, K, Befon, S, Hondros, K, Kouskouni, E, Vlahos, L. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. J Pain Symptom Management
1999; 18: 323–30.
Mercadante, S, Spoldi, E, Caraceni, A, Maddaloni, S, Simonetti, MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliative Medicine
1993; 7: 295–99.
Leveque, D. Subcutaneous administration of anticancer agents. Anticancer Res
2014; 34: 1579–86.
Migliore, A, Bizzi, E, Bernardi, M, Picchianti Diamanti, A, Lagana, B, Petrella, L. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clinical Drug Investigation
Torgerson, TR. Overview of routes of IgG administration. J Clin Immunol
(suppl 2): S87–89.
Jay, R. Methotrexate revisited: considerations for subcutaneous administration in RA. Clinical Rheumatology
Braun, J, Kastner, P, Flaxenberg, P, Wahrisch, J, Hanke, P, Demary, W
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheumatism
2008; 58: 73–81.
Gould, MK, Dembitzer, AD, Doyle, RL, Hastie, TJ, Garber, AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Annals Internal Med
1999; 130: 800–9.
Remi, C, Albrecht, E. Subcutaneous use of baclofen. J Pain Symptom Management
2014; 48: e1–3.
Simons, FE, Gu, X, Simons, KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clinical Immunol
2001; 108: 871–73.
Simpson, RG. Hyaluronidase in geriatric therapy. The Practitioner
1977; 219: 361–63.
Dychter, SS, Harrigan, R, Bahn, JD, Printz, MA, Sugarman, BJ, DeNoia, E
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. Clinical Therapeutics
2014; 36: 211–24.
Sandoval, M, Coleman, P, Govani, R, Siddiqui, S, Todd, KH. Pilot study of human recombinant hyaluronidase-enhanced subcutaneous hydration and opioid administration for sickle cell disease acute pain episodes. J Pain Palliative Care Pharmacotherapy
2013; 27: 10–18.
Vaughn, DE, Muchmore, DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion. Endocrine Practice
2011; 17: 914–21.
Muchmore, DB, Vaughn, DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Science Technol
2012; 6: 764–72.
Frost, GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opinion Drug Delivery
2007; 4: 427–40.
Ward, WK, Castle, JR, Branigan, DL, Massoud, RG, El Youssef, J. Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 versus pH 10. Clinical Drug Investigation
2012; 32: 433–38.
Laursen, T, Hansen, B, Fisker, S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clinical Pharmacol Toxicol
2006; 98: 218–21.
Harbour, R, Miller, J. A new system for grading recommendations in evidence based guidelines. BMJ
2001; 323: 334–36.
Borner, K, Lode, H, Hampel, B, Pfeuffer, M, Koeppe, P. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy
1985; 31: 237–45.
Melin-Coviaux, F HL, Hurtel, AS, Andrejak, M, Grumbach, Y. Etude pharmaco-clinique comparative de la ceftriaxone par voie sous-cutanée et intraveineuse chez la personne âgée. Rev gériatr
2000; 25: 10.
Bricaire, F, Castaing, JL, Pocidalo, JJ, Vilde, JL. [Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration]. Pathologie-biologie
1988; 36: 702–5.
Gauthier, D, Schambach, S, Crouzet, J, Sirvain, S, Fraisse, T. Subcutaneous and intravenous ceftriaxone administration in patients more than 75 years of age. Medecine et maladies infectieuses
2014; 44: 275–80.
Tailandier. Nécroses cutanées induites par la gentamicine sous-cutanée. Presse Med
1984; 13: 2.
Doutre. Nécroses cutanées après administration sous-cutanée de gentamicine. Therapie
1985; 40: 2.
Farless, LB, Steil, N, Williams, BR, Bailey, FA. Intermittent subcutaneous furosemide: parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. American J Hospice Palliative Care
2013; 30: 791–92.
Zacharias, H, Raw, J, Nunn, A, Parsons, S, Johnson, M. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?
2011; 25: 658–63.
Austin, J, Hockey, D, Williams, WR, Hutchison, S. Assessing parenteral diuretic treatment of decompensated heart failure in the community. Br J Community Nursing
2013; 18: 528, 30–34.
Zatarain-Nicolas, E, Lopez-Diaz, J, de la Fuente-Galan, L, Garcia-Pardo, H, Recio-Platero, A, San Roman-Calvar, JA. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience. Revista espanola de cardiologia (English edn). 2013; 66: 1002–4.
Mulvenna, PM, Regnard, CF. Subcutaneous ondansetron. Lancet
1992; 339: 1059.
Myers, KG, Trotman, IF. Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgraduate Medical J
1994; 70: 359–62.
Mathew, P, Storey, P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Management
1999; 18: 49–52.
Centeno, C, Vara, F. Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliative Care Pharmacotherapy
2005; 19: 7–12.
Jabalameli, M, Kalantari, F. Evaluation of the analgesic effect of subcutaneous methadone after cesarean section. Advanced Biomedical Res
2014; 3: 197.
Porteous, A, Robson, P, Lee, M. End-of-life management of patients who have been established on oral methadone for pain control. J Palliative Medicine
2013; 16: 820.
Kawamata, T, Sato, Y, Niiyama, Y, Omote, K, Namiki, A. Pain management after lumbar spinal fusion surgery using continuous subcutaneous infusion of buprenorphine. J Anesthesia
2005; 19: 199–203.
Kronenberg, RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliative Care Pharmacotherapy
2002; 16: 27–35.
Webster, LR, Walker, MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Am J Therapeutics
2006; 13: 300–5.
Mercadante, S, Lodi, F, Sapio, M, Calligara, M, Serretta, R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Management
1995; 10: 564–68.
Oshima, E, Tei, K, Kayazawa, H, Urabe, N. Continuous subcutaneous injection of ketamine for cancer pain. Canadian J Anaesthesia
1990; 37: 385–86.
Thomas, JR, Yocum, RC, Haller, MF, von Gunten, CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliative Medicine
2007; 10: 1312–20.
Pirrello, RD, Ting Chen, C, Thomas, SH. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliative Medicine
2007; 10: 861–64.
Allen, CH, Etzwiler, LS, Miller, MK, Maher, G, Mace, S, Hostetler, MA
Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics
2009; 124: e858–67.
Yocum, RC, Kennard, D, Heiner, LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infusion Nursing
2007; 30: 293–99.
Thomas, JR, Yocum, RC, Haller, MF, Flament, J. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Management
2009; 38: 673–82.
Morrow, L, Muchmore, DB, Hompesch, M, Ludington, EA, Vaughn, DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care
2013; 36: 273–75.
Garg, SK, Buse, JB, Skyler, JS, Vaughn, DE, Muchmore, DB. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes Obesity Metab
2014; 16: 1065–69.
Wilson, A, Patel, V, Chande, N, Ponich, T, Urquhart, B, Asher, L
Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Alimentary Pharmacol Therapeutics
2013; 37: 340–45.
Schiff, MH, Jaffe, JS, Freundlich, B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/ = 15 mg may be overcome with subcutaneous administration. Annals Rheumatic Diseases
2014; 73: 1549–51.
Demary, W, Schwenke, H, Rockwitz, K, Kastner, P, Liebhaber, A, Schoo, U
Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Preference Adherence
2014; 8: 1061–71.
Balis, FM, Mirro, J Jr, Reaman, GH, Evans, WE, McCully, C, Doherty, KM
Pharmacokinetics of subcutaneous methotrexate. Journal Clin Oncology
1988; 6: 1882–86.
Slevin, ML, Piall, EM, Johnston, A, Levison, DA, Aherne, GW, Tree, SB
The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension. Investigational New Drugs
1984; 2: 271–76.
Slevin, ML, Piall, EM, Aherne, GW, Johnston, A, Sweatman, MC, Lister, TA. The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br J Clin Pharmacol
1981; 12: 507–10.
Slevin, ML, Piall, EM, Aherne, GW, Johnston, A, Lister, TA. Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion. Cancer Chemotherapy Pharmacol
1983; 10: 112–14.
Marcucci, G, Silverman, L, Eller, M, Lintz, L, Beach, CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol
2005; 45: 597–602.
Juliusson, G, Samuelsson, H. Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. Leukemia Lymphoma
(suppl 2): 46–49.
Moreau, P, Pylypenko, H, Grosicki, S, Karamanesht, I, Leleu, X, Grishunina, M
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology
2011; 12: 431–40.
Moreau, P, Coiteux, V, Hulin, C, Leleu, X, van de Velde, H, Acharya, M
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica
2008; 93: 1908–11.
Nemunaitis, J, Mita, A, Stephenson, J, Mita, MM, Sarantopoulos, J, Padmanabhan-Iyer, S
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemotherapy Pharmacol
2013; 71: 35–41.
Lundin, J, Kimby, E, Bjorkholm, M, Broliden, PA, Celsing, F, Hjalmar, V
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood
2002; 100: 768–73.
Stilgenbauer, S, Zenz, T, Winkler, D, Buhler, A, Schlenk, RF, Groner, S
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncology
2009; 27: 3994–4001.
Wynne, C, Harvey, V, Schwabe, C, Waaka, D, McIntyre, C, Bittner, B. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clinical Pharmacol
Ismael, G, Hegg, R, Muehlbauer, S, Heinzmann, D, Lum, B, Kim, SB
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology
2012; 13: 869–78.
Pivot, X, Gligorov, J, Muller, V, Curigliano, G, Knoop, A, Verma, S
Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals Oncology
2014; 25: 1979–87.
Jackisch, C, Kim, S, Semiglazov, V, Melichar, B, Pivot, X, Hillenbach, C
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Annals Oncology